Publications
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Abstract
BACKGROUND: Patients with metastatic colorectal cancer whose disease has progressed on oxaliplatin- and irinotecan-containing regimens may benefit from EGFR-inhibiting monoclonal antibodies if they do not contain mutations in the KRAS gene (are
| Type | Journal |
|---|---|
| ISBN | 1471-2407 (Electronic) 1471-2407 (Linking) |
| Authors | Segelov, E.; Waring, P.; Desai, J.; Wilson, K.; Gebski, V.; Thavaneswaran, S.; Elez, E.; Underhill, C.; Pavlakis, N.; Chantrill, L.; Nott, L.; Jefford, M.; Khasraw, M.; Day, F.; Wasan, H.; Ciardiello, F.; Karapetis, C.; Joubert, W.; van Hazel, G.; Haydon, A.; Price, T.; Tejpar, S.; Tebbutt, N.; Shapiro, J.; |
| Publisher Name | BMC Cancer |
| Published Date | 2016-05-01 |
| Published Volume | 16 |
| Published Pages | 339 |
| Status | Published in-print |